Yuki Misumi

Yokohama, Japan

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Intraoperative pulmonary air-leak sites in catamenial pneumothorax: a retrospective 15-case surgical series.

Intraoperative pulmonary air-leak sites in catamenial pneumothorax: a retrospective 15-case surgical series.

Journal: Journal of thoracic disease
Published: May 19, 2026

Lung Abscess Caused by Pseudomonas aeruginosa after a Near-drowning Episode.

Lung Abscess Caused by Pseudomonas aeruginosa after a Near-drowning Episode.

Journal: Internal medicine (Tokyo, Japan)
Published: September 18, 2025

Platinum plus etoposide with durvalumab for extensive-stage small-cell lung cancer with untreated brain metastases: a multicenter, single-arm phase II trial (LOGiK2001, SPEED).

Platinum plus etoposide with durvalumab for extensive-stage small-cell lung cancer with untreated brain metastases: a multicenter, single-arm phase II trial (LOGiK2001, SPEED).

Journal: ESMO open
Published: March 03, 2025

Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study.

Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study.

Journal: Therapeutic advances in medical oncology
Published: October 16, 2024

Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitors.

Prognostic value of systemic immune-inflammation index in patients with small-cell lung cancer treated with immune checkpoint inhibitors.

Journal: BMC cancer
Published: October 14, 2024

Optimal Therapy for Postoperative Recurrence: Does Salvage Radiation Work for Locoregional Recurrence?

Optimal Therapy for Postoperative Recurrence: Does Salvage Radiation Work for Locoregional Recurrence?

Journal: Anticancer research
Published: September 30, 2024

Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study.

Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study.

Journal: Therapeutic advances in medical oncology
Published: July 10, 2024

Multiple lung abscesses and cold agglutinin syndrome following coronavirus disease 2019: a case report.

Multiple lung abscesses and cold agglutinin syndrome following coronavirus disease 2019: a case report.

Journal: Journal of medical case reports
Published: October 06, 2023

Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study).

Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non-small Cell Lung Cancer: TORG1937 (DATE Study).

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 21, 2023

Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study.

Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study.

Journal: JTO clinical and research reports
Published: June 28, 2023

Association of PD-L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR-mutated NSCLC.

Association of PD-L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR-mutated NSCLC.

Journal: Cancer medicine
Published: May 16, 2023

Entrectinib Response to ROS1-Fusion-Positive Non-Small-Cell Lung Cancer That Progressed on Crizotinib with Leptomeningeal Metastasis: A Case Report.

Entrectinib Response to ROS1-Fusion-Positive Non-Small-Cell Lung Cancer That Progressed on Crizotinib with Leptomeningeal Metastasis: A Case Report.

Journal: Case reports in oncology
Published: March 18, 2023
Showing 1-12 of 29

Last Updated: 09/26/2026